- About
- PsychU For You
- Topics
- Events
- Content
Exploring Unresolved Symptoms In Major Depressive Disorder (MDD): Potential Role Of Norepinephrine
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Exploring Unresolved Symptoms In Major Depressive Disorder (MDD): Potential Role Of Norepinephrine
Join us for a PsychU webinar exploring unresolved symptoms in major depressive disorder (MDD) and the potential role of norepinephrine, as part of the monoaminergic theory of depression.
Despite the efficacy of first-line anti-depressant treatments in MDD, many individuals continue to experience unresolved symptoms that may impair their daily functioning and increase the healthcare burden. In fact, the STAR*D study demonstrated approximately one third of patients with MDD achieved remission following treatment with first-line antidepressants, highlighting the need to address unresolved and persistent symptoms of depression.1 Recent studies have shown that norepinephrine, a neurotransmitter which regulates concentration, energy levels, and arousal, may play a crucial role in the persistence of depression symptoms.2
Please join Drs. Roger McIntyre and John Awad as they discuss the potential role of norepinephrine in depression and the challenges of identifying and treating unresolved depression symptoms. Our webinar aims to provide valuable insights into the complex nature of depression and the potential for treatments to address unresolved symptoms of depression.
References:- Rush AJ et al. Am J Psychiatry. 2006;163:1905-1917
- Maletic V, et al. Front Psychiatry. 2017;8:42.
Roger S. McIntyre, MD, FRCPC
Professor of Psychiatry and Pharmacology, University of Toronto, Head of the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto, Canada
MoreDr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.
Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada. Dr. McIntyre is also Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA. Dr. McIntyre is also Professor and Nanshan Scholar at Guangzhou Medical University, and Adjunct Professor College of Medicine at Korea University. Dr. McIntyre is also Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA and Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA. Dr. McIntyre is the founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE).
Dr. McIntyre was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019 and 2020 as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has published more than 650 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.
Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.
Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.
Dr. McIntyre is the lead author for the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder. Dr. McIntyre is also a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders.
Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.
John Awad, MD (OPDC)
Senior Medical Science Liaison
Related Events
Speaker Roger S. McIntyre, MD, FRCPC is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker John Awad, MD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Registration
- PsychU For You
